Follow

The subscription period in LIDDS’ rights issue is starting today and the CEO has participated in an interview with Erik Penser Bank

23 January 2023 - 13:00

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA, THE UNITED STATES OR ANY OTHER JURISDICTION, WHERE SUCH ACTIONS ARE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER REGARDING ANY SECURITIES IN LIDDS AB. SEE ALSO THE “IMPORTANT INFORMATION” SECTION BELOW.

The subscription period in the capital raising of LIDDS AB (publ) (”LIDDS” or the ”Company”) starts today and runs until February 6, 2023. Due to this, LIDDS would like to inform that Erik Penser Bank has published an interview with the Company’s CEO, Anders Månsson, who is presenting the Company’s operations and future plans.

The interview is available on Erik Penser Bank’s Youtube channel and can be viewed at: https://youtu.be/tjCjmfH5wg0

Advisors

Erik Penser Bank AB is financial advisor to LIDDS in connection with the share issue and Setterwalls Advokatbyrå AB is legal advisor.

Provided by: MFN
Nasdaq First North GM Stockholm (Sweden)
Lidds AB
Lidds is a Swedish pharmaceutical company developing innovative pharmaceutical products based on medical need and its proprietary drug delivery technology....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More